Skip to content
Back
  • Home
  • About us
    • Company focus
    • Management
    • Board
    • Team
    • Scientific advisory board
    • Partnerships
    • Investors
  • Our science
    • R&D Focus
    • R&D Levers
  • Pipeline
    • Pipeline
    • JM-010
    • CP-012
    • Discovery
  • News
    • Press releases
    • Upcoming events
  • Contact
    • Business Development
    • Social network

Our
Board

See our board

Dr. Hee-Won Yoo

Dr. Hee-Won Yoo is the CEO and President of Bukwang Pharmaceutical Co., Ltd, an R&D-focused Korean pharmaceutical company. Since her inauguration, Bukwang has made successful and outstanding footprints especially for new drug development and bio-venture investment by leveraging her extensive experiences and devotion. Prior to her current CEO post, she was deeply involved in the multi-national development and registration of several new drugs in joint projects with US and Japan based corporations. She has extensive experiences in a Korean bio-venture environment, with roles covering the establishment of bio-venture and development of drug products to commercialization.

Hee-Won received her Ph.D in Medicinal Chemistry from the School of Pharmacy at Ewha Women’s University in Korea. She then carried out her postdoctoral training in Chemistry of Carcinogenesis Laboratory at NIH in the US.

Mr. Sun Ho Kim

Mr. Sun Ho Kim is a Sr. Managing Director for Manufacturing in Bukwang Pharmaceutical Co., Ltd.

He has been dedicated to quality control and manufacturing field since he joined Bukwang. Prior to joining the company, Mr. Kim had worked for prestigious pharmaceutical companies in Korea like Yuhan, SK Chemical and Daewong. Now, he has around 30 years experience in pharmaceutical industry. Mr. Kim is a licensed pharmacist.

He graduated from Sungkyunkwan University, majored in Pharmacy.

 

Recent News

September 27, 2022
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…
Read more
September 08, 2022
Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery…
Read more

View all news

Contact us

Denmark map icon

Contera Pharma Headquarter

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

Thomas Sager, CEO
info@conterapharma.com

South Korea map icon

Contera Pharma Korea

7, SangDo-Ro, Dongjak-Gu
Seoul, 06955
Korea

info@conterapharma.com

Contact us

Contera Pharma Headquarter

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

 

Thomas Sager, CEO

info@conterapharma.com

Contera Pharma Korea

7, SangDo-Ro,

Dongjak-Gu

Seoul, 06955

Korea

info@conterapharma.com

Connect on Linkedin

Useful links

About us

Our Science

Pipeline

News

Contact

Cookie policy

Privacy policy

Bukwang

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years.

Discover Bukwang

Designet af Standoutmedia